IL-17-producing CD4 + cells (T H 17) are pathogenically linked to autoimmunity including to autoimmune kidney disease. Erythropoietin's (EPO) newly recognized immunoregulatory functions and its predominant intra-renal source suggested that EPO physiologically regulates T H 17 differentiation, thereby serving as a barrier to the development of autoimmune kidney disease. Using in vitro studies of human and murine cells and in vivo models, we show that EPO ligation of its receptor (EPO-R) on CD4 + T cells directly inhibits T H 17 generation and promotes trans-differentiation of T H 17 into IL-17 -FOXP3 + CD4 + T cells. Mechanistically, EPO/EPO-R ligation abrogates upregulation of SGK1 gene expression and blocks p38 activity to prevent SGK1 phosphorylation, thereby inhibiting RORC-mediated transcription of IL-17 and IL-23 receptor genes. In a murine model of T H 17-dependent aristolochic acid (ArA)-induced, interstitial kidney disease associated with reduced renal EPO production, we demonstrate that transgenic EPO overexpression or recombinant EPO (rEPO) administration limits T H 17 formation and clinical/histological disease expression.
INTRODUCTION
According to current concepts, in mucosal tissues continuously exposed to commensal microbes, e.g. the gastrointestinal tract, the genitourinary tract, and the pulmonary system, immune quiescence is constitutively maintained through innate and adaptive immune mechanisms that include the preferential generation of regulatory T cells (TREG) (1, 2) . In the gastrointestinal tract, this TREG-dependent immunoregulation requires local production of retinoic acid and/or TGFb (3) to drive FOXP3 expression in differentiating TREG. In these organs, infection with pathogenic microbes shifts the immune response toward IL-17 and IL-23 production, a process that is dependent on IL-6/TGFb-induced upregulation of transcription factor Retinoic acid-related orphan receptor gamma T (RORgt) within the T cells. The induced TH17 responses facilitate neutrophil recruitment, among other mechanisms, to promote pathogen clearance (3) . In these mucosal sites, once the infection has resolved, the proinflammatory immune response contracts and the immune regulation is restored. While many mechanisms underlying gastrointestinal immunoregulation are understood (1) , whether and how they apply to immune responses within the kidney remain unclear.
It is also increasingly recognized that aberrant TH17 responses can develop within mucosal organs and as a consequence can cause organ inflammation, injury and dysfunction. Examples include experimental colitis (4), autoimmune lung disease (5), lung transplant rejection (6) , and various forms of immune mediated kidney disease, e.g. experimental glomerulonephritis (7) , murine models of lupus nephritis (8) and toxininduced interstitial nephritis (9) . Whether and if so how local immunoregulatory mechanisms are compromised in these disease processes remains unclear.
Erythropoietin (EPO) is a protein predominantly produced by the kidney in adults and is required for red blood cell production (10, 11) . EPO is also produced by monocytes (12) and has increasingly been recognized to exhibit non-erythropoietic effects including immune modulation (12, 13) . In previous work, we added to the mechanistic understanding that links EPO to immunoregulation by first demonstrating that EPO ligates T cell-expressed EPO receptors (EPO-R), uncouples IL-2 receptor signaling, and thereby inhibits conventional T cell (TCONV) proliferation and TH1 differentiation (14) . In separate studies we showed that EPO promotes TREG induction and expansion via stimulating release and activation of TGFb by antigen presenting cells (APCs), which in turn induces conversion of naïve CD4 + T cells into induced TREG, and promotes kidney transplant acceptance (14, 15) .
Intriguingly, EPO is often reduced in TH17-associated immune mediated kidney diseases (16, 17) . We hypothesized that the immunoregulatory functions of EPO locally and crucially modulate TH17 differentiation and the development and/or severity of IL-17 associated disease processes. Herein, we used in vitro systems with human and murine cells as well as multiple in vivo TH17-dependent murine models to test this hypothesis.
RESULTS

EPO directly inhibits TH17 differentiation in vitro
Building upon our previous documentation that EPO inhibits T cell proliferation (14) polarizing conditions, we observed that addition of rEPO significantly inhibited these induced changes ( Figure 1A-B) . To test the effects of EPO under stronger TH17 inducing conditions, we exposed the T cells to increasing concentrations of NaCl (or urea as an osmotic control), a stimulus that was previously shown to augment TH17 polarization (18, 19) . Whereas addition of NaCl (but not urea) to the cultures augmented RORC and IL17 gene expression, rEPO blunted the increases ( Figure 1A-B) . EPO analogously and significantly reduced frequencies of IL-17-producing TH17 cells analyzed on day 5, in the presence or absence of elevated NaCl concentrations (Figure 1C-D) . To exclude the possibility that reduced TH17 induction with rEPO was mediated by T cell apoptosis and death, we stained cells for annexin V and 7AAD ( Figure 1E and Supplemental Figure   S1 ). These analyses showed no differences in cell viability and apoptosis, supporting the conclusion that rEPO inhibits TH17 differentiation without affecting cell survival.
EPO-induced inhibition of TH17 induction associates with decreased p38 and SGK1 phosphorylation
We hypothesized that EPO ligation of EPO-R on the responding T cells inhibits signals that induce upregulation of RORgt and IL-17 under TH17 polarizing conditions. We Current concepts are that phosphorylation of SGK1 (20) , a serine-threonine kinase that phosphorylates the transcription factor forkhead box protein O1 (FOXO1), is crucial for TH17 cell induction. Phospho-SGK1 (pSGK1) abrogates the suppressive effects of FOXO1 on RORgt-mediated Il23r expression, thereby enhancing IL-23R expression and TH17 cell stability (20) . Sodium increases TH17 induction by promoting transcription of Sgk1 gene and SGK1 protein phosphorylation (19) . To test whether EPO affects TH17
induction by counteracting SGK1 transcription and phosphorylation, we cultured human T cells with NaCl (or urea) ± EPO for 60 minutes and tested for SGK1 mRNA expression by qRT-PCR (Figure 2A) . Whereas NaCl significantly increased SGK1 mRNA compared to media alone or urea [verifying previously published work by others (19) ], EPO prevented the NaCl-induced SGK1 upregulation. NaCl-driven changes in SGK1 gene expression were mirrored by increases in IL17 and IL23R mRNA, while FOXO1 expression levels diminished (Supplemental Figure S3 ; see Supplemental Figure S4 for a schematic of the signaling pathway), supporting the previously described link between SGK1 and these mediators of TH17 induction (20) . EPO-induced inhibition of SGK1 gene expression was associated with reduction of IL17 and IL23R and increase of FOXO1 mRNA, indicating that EPO inhibits SGK1 activation and its linked, downstream effectors (Supplemental Figure S3 ). When we analyzed the kinetics of pSGK1 expression by phospho-flow cytometry, we confirmed that NaCl significantly increased pSGK1 compared to standard culture media, and newly showed that EPO fully abrogated the NaCl-induced increase in pSGK1 (Figure 2B-C) .
We repeated the TH17 induction cultures in the presence or absence of a selective SGK1
antagonist GSK650394 testing the effects on RORC, IL-17 and IL-23R ( Figure 2D -F and Supplemental Figure S5 ). While SGK1 inhibition reduced RORC and IL17 mRNA as well as IL-17 and IL-23R protein, rEPO had no additional inhibitory effects.
EPO inhibitory effects are overcome by p38 and SGK1 antagonism SGK1 phosphorylation is dependent upon p38 mitogen-activated protein (MAP) kinase (20) , which is also activated by NaCl (21) . To test whether EPO inhibitory effects on SGK1
are dependent upon inhibition of p38 phosphorylation, we repeated the TH17 induction cultures using human T cells exposed to NaCl or urea ± rEPO and measured phosphop38 (pp38) levels by flow cytometry (Figure 2G-H) . These analyses showed that EPO fully prevented the NaCl-induced increases in pp38.
To assess functional links among EPO, NaCl-induced pp38 and IL-17 production, we differentiated naïve human CD4 + T cells under TH17 polarizing conditions for 48 hours in the presence of NaCl and EPO, with or without the p38 activator anisomycin ( Figure 2I ). 
While rEPO inhibited
EPO directly inhibits TH17 differentiation in vivo
To test whether EPO inhibits TH17 differentiation in vivo independent of any effects of EPO on TREG generation (15) Diphteria toxin (DT) ( Figure 3A) , and verified that the DT treatment deleted FOXP3 + TREG in the adoptive hosts 1 week later (Supplemental Figure S6) . We then treated the animals with rEPO (1000 IU/kg) or saline control three times/week and analyzed frequencies of cytokine-producing CD4 + T cells 6 weeks after the adoptive transfer. These analyses showed that spleens of control animals (DT + vehicle) contained ~ 5% TH17
cells. In contrast, we observed a frequency of < 2.5% TH17 cells in spleens of the DT + rEPO-treated mice (P < 0.05, Figure 3B -C). We also observed fewer IFN-g + splenic CD4
+ T cells in the rEPO-treated mice ( Figure 3D -E). We did not detect FOXP3 + TREG in any of the recipients at the time of sacrifice (not shown). Together the data support the conclusion that EPO inhibits TH17 differentiation in vivo independent of indirect effects mediated via TREG that we reported previously (15) . 
EPO promotes conversion of TH17 cells into IL-17
EPO modulates TH17 immunity and renal injury induced by aristolochic acid
To test whether kidney-produced EPO influences development/expression of TH17-mediated kidney disease, we employed the aristolochic acid (ArA) model of murine nephropathy. ArA is the etiologic agent of human Balkan or Chinese herb nephropathy, a form of interstitial nephritis manifested as renal insufficiency and urinary protein loss (24, 25) . Interestingly, ArA nephropathy in humans is strongly associated with low serum EPO levels and with abnormalities in the IL-17/IL-17R axis (26) . Administration of ArA to B6 mice mimics many aspects of this human disease (27) .
We administered a 3-week course of ArA or vehicle control to B6 mice given a standard diet. Three weeks later (6 weeks after initiating the experiment), the animals developed Using an alternative therapeutic strategy, we tested the effects of rEPO administration on kidney disease and TH17 cells in ArA-treated mice. We fed groups of ArA-treated WT mice with control vs. high-NaCl diet and administered rEPO or vehicle ( Figure 6A ).
Increased albuminuria observed in the animals fed a high-NaCl diet was fully prevented by rEPO ( Figure 6B) . Administration of rEPO also counteracted the NaCl-induced changes in renal Rorc and Foxp3 gene expression ( Figure 6C ) and fully prevented the increase in TH17 cells (Figure 6D-E) , together normalizing TREG/TH17 ratio to control values ( Figure 6F-H) . High-NaCl diet increased IFN-g-producing CD4 + T cells in ArA treated mice (Supplemental Figure S8) , which was also prevented by rEPO administration.
Endogenous and recombinant EPO reduces TH17 and increases TREG, while lessening disease severity in pristane-induced lupus
To test whether EPO inhibits/reverses TH17-associated autoimmunity in another kidney disease model, we next studied pristane-induced nephritis in B6 mice (28, 29) , a kidney disease model that mimics some aspects of lupus nephritis and is known to be driven by TH17 immunity (30) . One week after initiating disease in B6 mice, we observed lower Epo mRNA expression in pristane vs control treated animals (0.09±0.08 vs. 0.92±0.10 fold expression; P < 0.05) (29) . Previous studies by others indicated that EPO/EPO-R signaling on monocyte/macrophages modulates pristane-induced nephropathy by promoting clearance of apoptotic cells, whose accumulation elicits autoimmune response (Figure 7C-D) , and increased intrarenal expression of Rorc and
Il17 genes (Figure 7E-F) .
In a converse strategy, we tested whether administration of rEPO dampens the clinical and immunological manifestation of pristane-induced nephropathy. We administered rEPO (or vehicle control) at 2 months after pristane injection and followed the animals for Our mechanistic analyses using in vitro and in vivo systems show that EPO directly binds to T cell expressed EPO-R to inhibit SGK1 signaling axis, a crucial pathway for TH17 induction (38) . During TH17 differentiation, transcription of SGK1 increases (19) as well as SGK1 activation by p38 (21) . This leads to phosphorylation and inhibition of FOXO1, a direct repressor of IL-23R expression (19) . Our studies demonstrate that EPO/EPO-R signaling inhibits SGK1 transcription and restrains activation of p38 and SGK1. Together, the data provide evidence that EPO directly counteracts TH17 induction at the molecular level. Importantly, our in vivo data show that intrarenal EPO regulates severity of renal disease in three TH17-mediated murine models. Similar to Balkan nephropathy in humans, the clinically relevant ArA nephropathy model is characterized by reduced EPO expression, tubulointerstitial fibrosis, and T cell infiltrates (27) . In this model, both transgenically increased endogenous EPO and administration of rEPO improved disease severity and reduced intrarenal expression of Rorc and Il17 genes and peripheral TH17 cells. The renal inflammation observed in this disease seems therefore driven or largely sustained by the reduced EPO levels, a consequence of the ArA-induced damage to EPO-producing cells (16, 17) . Together with previous data by others (39) showing that EPO confers protection against acute tubular damage and attenuated interstitial fibrosis in a mouse model of ArA nephropathy, our findings provide a rationale for studies testing rEPO as a therapeutic strategy to treat renal and immune abnormalities in subjects with Balkan nephropathy. In this model, we also documented that NaCl, while representing a major driver for RORC expression and TH17 differentiation, also promotes EPO production by the kidney (40, 41) . While the two mechanisms are likely to be independent, our data suggest that NaCldriven EPO production may counteract further TH17 induction.
We also demonstrate that EPO inhibits TH17 immunity and ameliorates disease severity in pristane induced nephritis and in MRL-lpr mice, models of lupus nephritis characterized by elevations in TH17 immunity along with defects in TREG (42) . While previous data by others have shown that rEPO treatment prevents disease progression in both models, this has never been linked to a direct effect of EPO on T cells (12, 43) . Our data newly demonstrate that lupus nephritis is associated with reduced Epo gene expression and rEPO treatment prevents TH17 induction and increases TREG/TH17 ratio, a previously unrecognized effect targeting a crucial pathogenic mechanism (44).
Lack of EPO-R in T cells increases susceptibility to pristane-induced lupus in B6 mice, a strain that is relatively resistant to the development of disease (45), further supporting the importance of endogenous EPO in directly controlling TH17 formation through EPO-R signaling. Importantly, mice selectively lacking EPO-R in T cells are resistant to EPO inhibitory effects on TH17, further indicating that EPO also directly inhibits TH17 induction also in this in vivo model. Reduced EPO concentration or the presence of antibodies against EPO or EPO-R are common in human systemic lupus erythematosus (SLE) (46) and correlate with disease severity (47, 48) , along with percentages of TH17 cells (49), supporting a causal link amongst low EPO/EPO-R signaling, TH17 induction, and SLE activity in affected patients.
Collectively, our new data provide an explanation for previous studies reporting EPOinduced amelioration of experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, where TH17 play a pathogenic role (50) . Similarly, EPO treatment has been shown to reduce the severity of optic neuritis or multiple sclerosis in humans (51) (52) (53) , possibly as a consequence of its inhibitory effects on TH17 cells. While some of these results are possibly independent from the immunological effects of EPO, it is reasonable to speculate that others are, at least in part, linked to EPO-induced inhibition of autoreactive TH17 cells.
Our recently identified immune-modulating effects of EPO may be also responsible for the prolonged graft survival in renal transplant patients treated with high doses of rEPO (54) and are consistent with the high expression of EPO mRNA in renal allografts of immunologically tolerant cynomolgus monkeys (55) and with the reported association between EPO-R transcripts in PBMC from kidney transplant recipients and acute rejection (56) . Immune modulating effects of EPO may also be, at least in part, responsible for the its beneficial effects in patients on dialysis (57), whose chronic inflammatory state has been linked to increased cardiovascular risk (58) .
The balance between TH17 cells and TREG has emerged as a prominent factor in regulating cancer as well (59) and the fact that EPO shifts the ratio in favor of TREG may contribute to the accelerated cancer progression described in patients receiving rEPO therapy (60).
In conclusion, our in vitro and in vivo data describe a previously unrecognized effect of EPO in counteracting TH17 induction and promoting their conversion into TREG. While these findings may have therapeutic implications for autoimmune diseases, organ transplantation, and cancers, they also raise the intriguing idea that EPO, traditionally considered to be primarily important for red blood cell differentiation, also plays a role in preserving peripheral tolerance in the kidney.
METHODS
Isolation of human peripheral blood cell and T cell subsets
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats obtained from de-identified healthy donors (New York Blood Bank) through Ficoll-Hypaque (SIGMA LifeScience) density gradient centrifugation. CD4 + CD45RA + CD45RO -naïve T cells were enriched through magnetic isolation (Miltenyi Biotec) using AutoMACS (Miltenyi, Biotech) (> 95% purity).
TH17 induction
Naïve CD4 + T cells were cultured in X-VIVO20 medium (Lonza) supplemented with 50 U/ml penicillin/streptomycin (Sigma-Aldrich), 50 μM 2-β-mercaptoethanol (Gibco), 1%
human AB serum (Gemini), 2 mM L-glutamine (Sigma-Aldrich), 1% Sodium Pyruvate (Corning) and 1% Non Essential Amino Acids (Millipore). Additional human cytokines used were recombinant active TGF-b1 (10 ng/ml, Miltenyi Biotec), IL-6 (30 ng/ml, Cell Application), IL-23 (100 ng/ml, ProSpec), IL-1b (10 ng/ml, Cell Application), IL-21 (50 ng/ml, Cell Application). We also added anti-INFg (4 μg/ml, BD Biosciences) and anti-IL-4 (4 μg/ml BD Biosciences). Cells were activated with anti-CD3/anti-CD28 mAb beads (1µg/ml, BD Biosciences) and cultured with ± NaCl (20-40 mM) or Urea (40-80 mM) ± EPO (1000 IU/ml) for 5 days and collected for intracellular cytokine staining, flow cytometry and stained for apoptosis markers (annexin V/7-AAD, BD Pharmingen). RNA was collected at 24 hours to measure gene expression profile by Real-time PCR.
In some experiments, we used anisomycin (Sigma-Aldrich; 10 µg/ml) or GSK650394 (Tocris; 10nM) to activate p38 or inhibit Sgk1, respectively.
For TH17 induction with murine cells, naïve CD4 + T cells were obtained from the spleen and lymph nodes and cultured for 5 days with TGF-b1 (5 ng/ml, BioXcell) and IL-6 (30 ng/ml, Peprotech).
Flow cytometry
For surface staining, human cells were stained using standard approaches as published Data were acquired (10,000 to 100,000 events) on a three-laser Canto II flow cytometer (BD Biosciences) and analyzed using CytoBank (https://www.cytobank.org) or FlowJo (https://www.flowjo.com) software.
Real-time Quantitative Reverse Transcription-PCR
RNA was prepared from 0.5 cm of the mouse kidneys or from cultured naïve CD4 + T cells at day 3 of culture in TH17-polarizing conditions using Trizol (Invitrogen). cDNA was synthesized using reverse transcription reagent (Applied Biosystems ArA (Sigma Aldrich) was administered i.p. at the dose of 3mg/kg 3 times a week for 3 weeks. Pristane (Sigma Aldrich) was administered as a single i.p. 0.5ml dose. Diphteria toxin (Sigma Aldrich) was administered at the dose of 10µg/kg, i.p. x 3/week. Human rEPO alpha (Procrit) was obtained from Janssen-Cilag (Titusville, NJ).
Renal histology
Animals were deeply anesthetized, transcardially perfused with periodate-lysinparaformaldehyde fixate at 4 % in phosphate buffered saline (PBS), and the kidneys were dissected out. Kidney samples were either frozen in Optimal Cutting Temperature (O.C.T., Tissue-Tek) compound or fixed in 10% formalin and then embedded in paraffin.
Light microscopy
Formalin paraffin-embedded kidney sections (3 μm) were stained with H&E and Masson's trichrome to highlight interstitial fibrosis in ArA model. Histological scoring was performed in a blinded manner by a renal pathologist according to a previously established method (61) .
Immunofluorescence analysis in renal tissue
Samples 
EPO and Urine Albumin/Creatinine measurement
To quantify proteinuria, we measured urine creatinine and urine albumin concentration to calculate UACR. Urine creatinine was quantified using commercial kits from Cayman Chemical (Ann Arbor, MI). Urine albumin was determined using a commercial assay from Bethyl Laboratory Inc. (Houston, TX). Urine albumin excretion was expressed as the ratio of urine albumin to creatinine.
The concentration of EPO in cell culture supernatant samples was measured using commercial kits from Abcam (Cambridge, UK) according to the manufacturer's recommendations.
Statistics
We used paired or unpaired t-tests for two-group comparisons, and one-way, or two-way ANOVA (with Tukey test for post hoc pairwise differences) for multiple independent groups comparisons. A two-tailed p-value of less than 0.05 was regarded as statistically significant. All statistical analyses were performed using GraphPad Prism (version 7 for
Windows, GraphPad Software, Inc.). + cells after 5 days of culture (n = 6 mice per group). *P < 0.05 vs. vehicle; # P < 0.05 vs. media (no NaCl or urea), paired t-test or two-way ANOVA with Tukey test. N.s. stands for "not significant".
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